Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Phathom Pharmaceuticals ( (PHAT) ) is now available.
On January 7, 2026, Phathom Pharmaceuticals entered into an underwriting agreement with Guggenheim Securities and Cantor Fitzgerald for an underwritten public offering comprising 6,875,000 shares of common stock at $16.00 per share and 1,250,078 pre-funded warrants at $15.999 each, with a 30-day option for underwriters to purchase up to 1,218,761 additional shares. The underwriters agreed to purchase the securities at a discount, and Phathom expects to raise net proceeds of about $130 million, or approximately $150 million if the option is fully exercised, with the offering anticipated to close on January 9, 2026 subject to customary conditions; the company has said it plans to use the capital for general corporate purposes, including working capital and commercialization and R&D expenses, which would bolster its funding base for ongoing product rollouts and pipeline development in gastrointestinal therapeutics.
The most recent analyst rating on (PHAT) stock is a Hold with a $19.00 price target. To see the full list of analyst forecasts on Phathom Pharmaceuticals stock, see the PHAT Stock Forecast page.
Spark’s Take on PHAT Stock
According to Spark, TipRanks’ AI Analyst, PHAT is a Neutral.
Phathom Pharmaceuticals’ overall stock score reflects a mix of strong technical momentum and positive recent developments, tempered by significant financial challenges and valuation concerns. The company’s strategic focus and recent trial results are promising, but financial instability and reliance on external funding remain key risks.
To see Spark’s full report on PHAT stock, click here.
More about Phathom Pharmaceuticals
Phathom Pharmaceuticals, Inc., based in Florham Park, N.J., is a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases. The company has exclusive rights in the U.S., Europe and Canada to vonoprazan, a first-in-class potassium-competitive acid blocker, which it currently markets in the United States under the VOQUEZNA brand for multiple gastroesophageal reflux disease (GERD) indications and as VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK for the treatment of H. pylori infection in adults.
Average Trading Volume: 968,201
Technical Sentiment Signal: Buy
Current Market Cap: $1.16B
Find detailed analytics on PHAT stock on TipRanks’ Stock Analysis page.